Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.
about
Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA.Steroids in kidney transplant patientsGranzymes and perforin in solid organ transplant rejection.A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogsTolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplantsA prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantationTreatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids.Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-upRecent developments in kidney transplantation--a critical assessment.Safety of human neural stem cell transplantation in chronic spinal cord injury.Immunomodulatory drugs: oral and systemic adverse effects.Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.The need for minimization strategies: current problems of immunosuppression.The over-exaggerated chronic nephrotoxicity of calcineurin inhibitorsKidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair.Long-term renal allograft survival in the United States: a critical reappraisal.Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques.In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.Deceased-donor kidney transplantation: improvement in long-term survival.Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood.Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.
P2860
Q30411026-953C23E3-2A57-47CD-A0AA-9F95336FC677Q33768177-92D8EFEC-D383-420D-9882-44A6D1F218CEQ34093890-07A223FD-46DC-4262-BC2E-C589C43D46FEQ34124314-800A6DE9-D41D-46C5-8C0C-6BCE44602E9BQ34862560-1D636141-1DED-43A6-B4E1-0CDD6D339C1CQ35010452-2BF35DD6-4E26-4294-B13A-C750D358CD88Q35751578-3E9B8BEB-EE14-4E4C-9D96-469A18040295Q35918706-BF8F6EBE-EC73-4C6D-97B2-D81312080D18Q36183858-E902B8CD-214B-4517-AD6D-2AAFBDE34982Q36281955-CF9CFF3A-414E-4E80-B440-65956A50CEAFQ36538911-7CA09542-B458-4012-90E3-7153E95444F3Q36926228-CC02EC32-3FDE-4DE0-83CE-3BB77740E11AQ37301840-E1DE2879-FAA3-4552-9833-05196A4BD6A5Q37344279-1C81F983-7998-4632-89E8-0309BE24FCFEQ37539743-0B95AFD8-0540-4990-8B62-478B935CA53DQ37990988-39CD65AA-5A10-4636-A0C4-397C774DBB3DQ38230449-A77FB089-986D-482C-9F1C-714A2176263BQ38340831-77DC722F-E5B9-4C49-8984-92C8E9FDC902Q38370826-AD75C14F-9F8C-4482-B228-B5822BCC07CBQ38630386-ED231CEC-D67C-4FC7-875F-7E3C4F5D3CFCQ38658621-19B645D7-91B6-4E09-ABDE-FC42A23D58EAQ39824383-F7A531DB-EEB8-4806-B3FF-EE8DD91732D9Q41296016-4E660CA2-DA33-4F37-8C1E-6FB94AFF559AQ42222507-FF8976F6-2CB7-43C7-9097-07AA5FB6A856Q43182515-131A7ED9-FE43-4ADB-A401-054D1B6F9309Q46403947-C8253164-4042-47E6-9F7E-48FB4DBD0BDCQ51725975-6F9FAA72-B9FC-4DED-9891-36E6720C1306Q52888129-7DEA1B63-5462-4A84-8824-DD06ADC8BB6DQ54590640-8D447911-38BB-44B1-9B38-AB2EAD5E9A0B
P2860
Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minimizing immunosuppression, ...... objectives and interim result.
@en
Minimizing immunosuppression, ...... objectives and interim result.
@nl
type
label
Minimizing immunosuppression, ...... objectives and interim result.
@en
Minimizing immunosuppression, ...... objectives and interim result.
@nl
prefLabel
Minimizing immunosuppression, ...... objectives and interim result.
@en
Minimizing immunosuppression, ...... objectives and interim result.
@nl
P2860
P356
P1476
Minimizing immunosuppression, ...... objectives and interim result.
@en
P2093
Herwig-Ulf Meier-Kriesche
Titte R Srinivas
P2860
P304
P356
10.2215/CJN.03510807
P478
P577
2008-03-01T00:00:00Z